Cardiomyopathy treatments
List of Mavacamten prescription centers by region. Updated January 2026.
Patients with hypertrophic obstructive cardiomyopathy can consult the AICARM website for an updated list of centers authorized to prescribe Mavacamten. The list, created in collaboration with AIFA, is organized by region and is a useful tool for identifying the appropriate specialist facility.
Mavacamten is reimbursed by the National Health Service (NHS) for hypertrophic obstructive cardiomyopathy. Here are the timing, regional procedures, and prescribing centers.
Gliflozins, initially developed as diabetes drugs, have proven to be one of the greatest revolutions in heart failure treatment. Thanks to robust clinical trials, they have become the fourth pillar of therapy and are also showing benefits for the kidneys and, perhaps, even cardiac protection in oncology. A clear and up-to-date analysis of what patients and families need to know.
The Cardiomyopathy Diagnosis and Treatment Center in Florence: a center of excellence serving patients. The 2024 yearbook published by the Intercompany Center for Innovation and Research for the Diagnosis and Treatment of Cardiomyopathies, directed by Prof. Iacopo Olivotto, confirms the level of quality and excellence achieved.
Be careful not to consider rare diseases as marginal. This is the risk that, according to Professor Giuseppe Limongelli, director of the Rare and Hereditary Cardiovascular Diseases Unit at the Monaldi Hospital in Naples, is becoming concrete in "a healthcare system that is increasingly turning towards the private sector". The goal is to apply the National Rare Disease Plan and Law 175, so that no patient is left behind, explains Limongelli who recounts the path taken to create the team dedicated to rare genetic heart diseases.
In 2022, the University of Pisa, led by Professor Martina Smorti, launched a research study on the psychological and relational well-being of young people with cardiomyopathy. From the results of this study, an intervention project funded by AICARM Aps was launched, at the Cardiomyopathy Unit of the AOU Careggi-Firenze, whose first results seem to confirm how group meetings can constitute a support network to deal with the transition to adulthood.
The course on Obstructive Hypertrophic Cardiomyopathy, organized by AICARM Aps, saw the participation of the best Italian specialists. HCM surgery has made significant strides towards minimally invasive techniques, which reduces trauma and allows patients to quickly return to their daily lives. Clear information becomes important to encourage acceptance of the intervention. The establishment of a register of innovative therapies has been announced.
In women with different types of cardiomyopathy and who take antiplatelet or anticoagulant drugs, there is a risk of maternal or fetal hemorrhages and fetal malformations. For those who decide to embark on a pregnancy it is therefore necessary to request consultation in reference centers in order to carefully evaluate the risk and possible alternative therapy when possible. Here are some recommendations.
At the University of California San Diego (UCSD), the first gene therapy for a hereditary heart disease was developed: Danon disease, characterized by the accumulation of glycogen, due to variants in the gene that codes for a protein necessary for the elimination of cell phone waste. The type of gene therapy developed by the researchers consists of the LAMP2B gene contained in a virus capable of entering heart cells. The encouraging results of the research have allowed the experimentation to continue and a further study on male patients with Danon disease will soon begin in Europe. The only center in Italy invited to participate will be the AOU Meyer.
